KALA - FDA Oks Kala Pharma's Eysuvis for dry eye disease

The FDA has approved Kala Pharmaceuticals' (KALA) EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.“The FDA approval of EYSUVIS as the first prescription therapy specifically developed to address the short-term treatment needs of people living with dry eye disease is a major accomplishment for Kala and an important moment for patients, who have been waiting for an FDA-approved, safe, effective and fast-acting therapy,” said Mark Iwicki, Chairman, President and CEO.Shares +3% premarket.

For further details see:

FDA Oks Kala Pharma's Eysuvis for dry eye disease